The unfolded protein response transcription factor XBP1s ameliorates Alzheimer’s disease by improving synaptic function and proteostasis

• DOI: 10.1016/j.ymthe.2023.03.028
• Publication Date: 2023-04-04T01:23:26Z
• Authors: Claudia Duran-Aniotz; Natalia Poblete; Catalina Rivera-K...; Álvaro O. Ardiles; Mei Li Díaz-Hung; Giovanni Tamburini; Carleen Mae P. Sa...; Yannis Gerakis; Felipe Cabral-Mir...; Javier Diaz; Matias Fuentealba; Diego Arriagada; Ernesto Muñoz; Sandra Espinoza; Gabriela Martinez; Gabriel Quiroz; Pablo Sardi; Danilo B. Medinas; Darwin Contreras; Ricardo Piña; Mychael V. Lourenco; Felipe C. Ribeiro; Sergio T. Ferreira; Carlos Rozas; Bernardo Morales; Lars Plate; Christian Gonzale...; Adrian G. Palacios; Claudio Hetz
• Keywords: Proteomics; Mice; Alzheimer Disease; Proteostasis; Unfolded Protein Response; Animals; Mice, Transgenic; Endoplasmic Reticulum Stress; Signal Transduction; Transcription Factors

Alteration in the buffering capacity of the proteostasis network is an emerging feature of Alzheimer's disease (AD), highlighting the occurrence of endoplasmic reticulum (ER) stress. The unfolded protein response (UPR) is the main adaptive pathway to cope with protein folding stress at the ER. Inositol-requiring enzyme-1 (IRE1) operates as a central ER stress sensor, enabling the establishment of adaptive and repair programs through the control of the expression of the transcription factor X-box binding protein 1 (XBP1). To artificially enforce the adaptive capacity of the UPR in the AD brain, we developed strategies to express the active form of XBP1 in the brain. Overexpression of XBP1 in the nervous system using transgenic mice reduced the load of amyloid deposits and preserved synaptic and cognitive function. Moreover, local delivery of XBP1 into the hippocampus of an 5xFAD mice using adeno-associated vectors improved different AD features. XBP1 expression corrected a large proportion of the proteomic alterations observed in the AD model, restoring the levels of several synaptic proteins and factors involved in actin cytoskeleton regulation and axonal growth. Our results illustrate the therapeutic potential of targeting UPR-dependent gene expression programs as a strategy to ameliorate AD features and sustain synaptic function.